| Terminated | Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection NCT04539483 | Heidelberg ImmunoTherapeutics GmbH | Phase 2 |
| Terminated | A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis NCT03521479 | Squarex, LLC | Phase 2 |
| Completed | Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1) NCT03661541 | Squarex, LLC | Phase 1 |
| Completed | Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes L NCT02965781 | Squarex, LLC | Phase 1 / Phase 2 |
| Completed | Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes NCT02871492 | AiCuris Anti-infective Cures AG | Phase 2 |
| Unknown | Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis NCT02582086 | Laboratoire Boreaderme Inc. | N/A |
| Completed | Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores NCT02483182 | Shulov Innovate for Science Ltd. 2012 | Phase 2 |
| Completed | Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labia NCT02265913 | Padagis LLC | Phase 3 |
| Completed | A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labial NCT02207881 | Yung Shin Pharm. Ind. Co., Ltd. | Phase 2 |
| Completed | Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis NCT01971385 | Massachusetts General Hospital | Phase 1 |
| Unknown | NB-001 Treatment of Recurrent Herpes Labialis NCT01695187 | NanoBio Corporation | Phase 3 |
| Completed | An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode NCT01653509 | GlaxoSmithKline | Phase 1 |
| Completed | Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years O NCT01574612 | Meda Pharmaceuticals | Phase 3 |
| Completed | Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment o NCT01257074 | EMS | Phase 3 |
| Completed | Study of a Cold Sore Patch for the Treatment of Herpes Labialis NCT01484067 | Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc. | N/A |
| Recruiting | Viral Infections in Healthy and Immunocompromised Hosts NCT01306084 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis NCT03310294 | Sprim Advanced Life Sciences | N/A |
| Terminated | Botulinum Toxin A for Herpes Labialis NCT01225341 | DeNova Research | N/A |
| Terminated | A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurren NCT00913692 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Study to Evaluate Using a Cold Sore Patch to Treat Herpes Labialis NCT01208298 | Johnson & Johnson Consumer and Personal Products Worldwide | N/A |
| Completed | Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis NCT00878072 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Immune Response to the Consumption of Lactobacillus GG and FOS in Patients With Recurrent Herpes Labialis NCT03307772 | Sprim Advanced Life Sciences | N/A |
| Completed | Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers NCT00711776 | GlaxoSmithKline | Phase 1 |
| Completed | Phase 3 Clinical Study for the Treatment of Cold Sore NCT00769314 | Valerio Therapeutics | Phase 3 |
| Completed | Iontophoretic Application of Acyclovir Gel to Treat Cold Sores NCT00469300 | Transport Pharmaceuticals | Phase 2 |
| Completed | Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis NCT00453401 | NanoBio Corporation | Phase 2 |
| Completed | Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients NCT00735761 | Medivir | Phase 3 |
| Completed | Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents NCT00375570 | Medivir | Phase 3 |
| Completed | Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis NCT00361881 | Medivir | Phase 3 |
| Completed | VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2 NCT00306293 | GlaxoSmithKline | Phase 4 |
| Completed | Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis NCT00230867 | Transport Pharmaceuticals | Phase 2 |
| Completed | Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis NCT00297011 | University of Utah | Phase 2 |
| Completed | Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis NCT00736437 | Medivir | Phase 2 |